🔎 Trials Near Me

홈 › 버킷 림프종 › 아이다호

아이다호의 버킷 림프종 임상 시험

버킷 림프종 관련 연구 6개가 아이다호 내 여러 지역에서 참여자를 모집하고 있습니다.

아이다호의 도시

공식 연구 텍스트(영어)

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  • Saint Alphonsus Cancer Care Center-Nampa, Nampa
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT03739814

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • Saint Luke's Cancer Institute - Boise, Boise
피험자 모집 중2상
1세 ~ 30세 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT04546399

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

  • Saint Alphonsus Cancer Care Center-Boise, Boise
  • Saint Luke's Cancer Institute - Boise, Boise
  • Saint Alphonsus Cancer Care Center-Caldwell, Caldwell
  • 외 8개
피험자 모집 중3상
18세 ~ 39세 · 모든 성별 · 2026. 11. 3. 업데이트됨 · NCT03150693

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • Saint Luke's Cancer Institute - Boise, Boise
피험자 모집 중2상
365 Days · 모든 성별 · 2026. 10. 27. 업데이트됨 · NCT06317662

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • Saint Luke's Cancer Institute - Boise, Boise
피험자 모집 중2상
366 Days – 46 Years · 모든 성별 · 2026. 10. 27. 업데이트됨 · NCT06124157

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Saint Luke's Cancer Institute - Boise, Boise
피험자 모집 중3상
365 Days – 25 Years · 모든 성별 · 2026. 8. 25. 업데이트됨 · NCT03959085

ClinicalTrials.gov 출처, 2026. 11. 15. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.